The prodigal spinout returns? Since launching Grail into the world in 2016, Illumina has watched the blood test developer grow into a multibillion-dollar startup enterprise by amassing multiple nine-digit funding rounds. However, Grail’s spending has not been wasteful: It’s also collected clinical data from tens of thousands of patients in a massive bid to prove its liquid biopsy test can detect cancer early. But now, a week after it has filed to go public—and with commercial launches on the horizon next year—the DNA sequencing giant apparently has decided it’s time for Grail to come home.
Read the full article: Illumina in Talks to Reacquire Its Cancer Blood Test Spinout, Grail: Bloomberg //
Source: https://www.fiercebiotech.com/medtech/illumina-talks-to-reacquire-its-cancer-blood-test-spinout-grail-bloomberg